XYOSTED (testosterone enanthate)

SELF ADMINISTRATION - SUBCUTANEOUS INJECTION

Indications for Prior Authorization: 
  • Indicated for testosterone replacement in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary hypogonadism (congenital or acquired), and hypogonadotropic hypogonadism (congenital or acquired).
The following criteria must be met for coverage:
  • Patient is 18 years of age or older, AND
  • Diagnosis of hypogonadism confirmed by medical record documentation including lab documentation of morning serum testosterone concentrations below normal range, AND
  • Patient has persistent signs and symptoms (e.g., depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis, loss of libido) of androgen deficiency (pre-treatment), AND
  • Other reasons for androgen deficiency have been ruled out (e.g. adrenal insufficiency, hypopituitarism), AND
  • Medical justification is provided why patient cannot use both topical testosterone (gel and patch), and testosterone for IM injection, AND
  • Blood pressure is adequately controlled
  • Limited to a 30 day supply per fill
  • Contraindicated in men with carcinomas of the breast or prostate
Dosing:
  • The starting dose of Xyosted is 75 mg, administered subcutaneously in the abdominal region once a week.
Approval: 
  • 1 year

Last review date: May 19, 2020